Diaphragmatic Function as a Biomarker
Trial statusRecruiting
Trial phaseNot listed
Trial typeObservational
Biological sexAll
Age18+
SponsorRWTH Aachen University
About this trial
Dyspnea is among the most common symptoms in patients with respiratory diseases such as Asthma, chronic obstructive pulmonary disease (COPD), Fibrosis, and Pulmonary Hypertension. However, the pathophysiology and underlying mechanisms of dyspnea in patients with respiratory diseases are still poorly understood. Diaphragm dysfunction might be highly prevalent in patients with dyspnea and respiratory diseases. The association of diaphragm function and potential prognostic significance in patients with respiratory diseases has not yet been investigated.
Eligibility criteria
Qualifiers
patient has one of the following lung diseases: COPD, bronchial asthma, pulmonary fibrosis, pulmonary hypertension
is 18 years or older
is mentally and physically able to understand the study and to follow instructions
are legally competent
Disqualifiers
BMI > 35
current or treatments or diseases in the past which could influence the evaluation of the study
Expected lack of willingness to actively participate in study-related measures
alcohol or drug abuse
Trial design
Treatments tested in this trial
- Diaphragm Ultrasound
- Intercostal Muscle Ultrasound
- Borg scale
- MRC Breathlessness Scale
- Respiratory Questionaire
- GINA classification of Asthma
- Measurement of respiratory mouth pressure
- SNIP
- 6-minute walking distance
- 60 seconds sit-to-stand test
- Electromyography
- Lung Function
- CAT-Questionnaire
- European Society of Cardiology (ESC)/ European Respiratory Society (ERS) risk group
Treatment groups
800 Participants
are divided into 4 treatment groupsSponsors and collaborators
Source ClinicalTrials.gov